Pharmaceutical composition

By using sulfated polysaccharides such as heparin-like and pentosan polysulfate as nasal polyps shrinkage agents, the problem of nasal polyps shrinkage is solved, and a safe and efficient nasal polyps shrinkage effect is achieved, which is suitable for a variety of sinusitis types.

CN118976045APending Publication Date: 2024-11-19UNIVERSITY OF FUKUI +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411053759.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2019-09-20
Filing Date
2020-09-18
Publication Date
2024-11-19

AI Technical Summary

Technical Problem

The prior art is difficult to effectively reduce nasal polyps, especially those related to eosinophilic sinusitis, and traditional treatment methods have recurrence problems.

Method used

Sulfated polysaccharides, such as heparinoids and pentosan polysulfate, are used as nasal polyps reduction agents, and are administered intranasal cavity to significantly reduce nasal polyps.

Benefits of technology

Sulfated polysaccharides significantly reduce nasal polyps at low doses and are safe. They are suitable for patients with eosinophilic sinusitis and non-eosinophilic sinusitis, improving symptoms such as nasal congestion.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118976045A_ABST
    Figure CN118976045A_ABST
Patent Text Reader

Abstract

The present invention relates to: a nasal polyp reducing agent, a pharmaceutical composition, a nasal polyp reducing method, or a method for preventing / treating nasal polyp; the nasal polyp reducing agent contains, as an active ingredient, a polysaccharide selected from the group consisting of polysulfated chondroitin sulfate, chondroitin sulfate, dermatan sulfate, keratin sulfate, heparan sulfate, dextran sulfate, pentosan polysulfate (PPS), chondroitin, glucomannan, inulin, and xylo-oligosaccharide, or a salt thereof. According to the present invention, an effective and safe nasal polyp reducing agent can be provided.
Need to check novelty before this filing date? Find Prior Art

Description

This application is a divisional application of a patent application with the original application date of September 18, 2020 (priority date of September 20, 2019), the original application number of 202080064874.7 (international application number of PCT / JP2020 / 035438), and the invention name of “Pharmaceutical Composition”. Technical Field

[0001] The present invention relates to a pharmaceutical composition containing a predetermined polysaccharide used as a nasal polyp reducing agent, or a method for treating nasal polyps using the predetermined polysaccharide. Background Art

[0002] Nasal polyps, also known as nasal polyposis, are fleshy growths of the nasal mucosa that develop in areas of the lamina propria (typically around the opening of the maxillary sinus) where dependent edema develops. This condition is often associated with chronic sinusitis, exacerbating the nasal congestion associated with chronic sinusitis and is a major nasal disease (MSD Manual Professional Edition, https: / / www.msdmanuals.com / ja-jp).

[0003] The causes of nasal polyps are believed to include edema caused by hyperpermeability of the vascular lamina propria, prolapse of the mucosal lamina propria, and accumulation of extracellular matrix. Furthermore, there are reports of associations with various cytokines and growth factors. As growth factors, vascular endothelial growth factor and platelet-derived growth factors have been reported to be associated with nasal polyps (Non-Patent Document 1: Journal of the Kawasaki Medical Association 35(1): 39-50, 2009).

[0004] Chronic sinusitis presents with respiratory symptoms such as nasal congestion, rhinorrhea, postnasal discharge, and cough, which persist for more than three months. Its causes include viral, bacterial, fungal, allergic, or unidentified eosinophilic causes. Furthermore, it can be complicated by factors such as differences in nasal morphology, living environment, and genetics, leading to the formation of nasal polyps (Non-Patent Literature 2: Journal of the Japanese Society of Otolaryngology 2018, 121, 1118-1120).

[0005] Chronic sinusitis with nasal polyps includes eosinophilic sinusitis and non-eosinophilic sinusitis. Eosinophilic sinusitis is a designated intractable disease, characterized by severe nasal congestion and olfactory impairment due to multiple bilateral nasal polyps and thick nasal discharge, making it a difficult-to-treat adult-onset sinusitis. Antibiotics are ineffective in treating this disease, and it responds only to oral steroids. Because the nasal cavity is filled with nasal polyps, sinus surgery is often performed to remove them, but this poses the risk of immediate recurrence.

[0006] As drug therapies for nasal polyps, there have been reports of the use of topical steroids, systemic steroids, monoclonal antibodies or antagonists against interleukin-4 (Patent Document 1: Japanese Patent 6463351), interferon (Patent Document 2: Japanese Patent Application Laid-Open No. 09-104636), aspirin powder (Patent Document 3: Japanese Patent Application Laid-Open No. 10-203988) and / or hyaluronic acid (Non-Patent Document 3: Indian Journal of Otolaryngology and Head & Neck Surgery 67(3):299-307, September 2015).

[0007] On the other hand, heparin, which has an anticoagulant effect, has been reported to significantly inhibit mucus production or neutrophil infiltration in a rat nasal mucosal inflammation model (Non-patent document 4: Otorhinolaryngology Allergy 29(3):221-227, 2011), but did not show a shrinking effect on nasal polyps collected from patients with eosinophilic sinusitis (Non-patent document 5: Allergology International 66(2017)594-602).

[0008] Prior art literature Patent Literature Patent Document 1: Japanese Patent 6463351; Patent Document 2: Japanese Patent Application Laid-Open No. 09-104636; Patent Document 3: Japanese Patent Application Laid-Open No. 10-203988; Non-patent literature Non-patent literature 1: Journal of Kawasaki Medical Association 35(1):39-50, 2009; Non-patent literature 2: Journal of the Japanese Society of Otolaryngology 2018, 121, 1118-1120; Non-patent literature 3: Indian Journal of Otolaryngology and Head & Neck Surgery 67(3):299-307, September 2015; Non-patent document 4: Ear and Nose Immunology 29(3):221-227, 2011; Non-patent document 5: Allergology International 66(2017)594-602. Summary of the Invention

[0009] Problems to be solved by the invention The present invention provides a safe nasal polyp reducing agent or a method for treating nasal polyps that exhibits an excellent shrinking effect on nasal polyps.

[0010] Means for solving problems As a result of intensive research, the present inventors have discovered that a predetermined polysaccharide, particularly heparinoid or pentosan polysulfate (PPS), which is one of the sulfated polysaccharides, significantly reduces the size of nasal polyps, thereby completing the present invention.

[0011] That is, the present invention is as follows.

[0012] (1) A nasal polyp shrinking agent comprising a polysaccharide or a salt thereof selected from polysulfated chondroitin sulfate, chondroitin sulfate, dermatan sulfate, keratan sulfate, heparan sulfate, dextran sulfate, pentosan polysulfate, chondroitin, glucomannan, inulin and xylo-oligosaccharide as an active ingredient.

[0013] (1a) The nasal polyp reduction agent described in (1), wherein the polysaccharide or its salt is selected from the group consisting of polysulfated chondroitin sulfate, chondroitin sulfate, keratan sulfate, heparan sulfate, dextran sulfate, pentosan polysulfate, chondroitin, glucomannan and inulin.

[0014] (1b) A nasal polyp shrinking agent comprising a sulfated polysaccharide or a salt thereof as an active ingredient.

[0015] (1c) The nasal polyp reduction agent described in (1b), wherein the sulfated polysaccharide or its salt is selected from polysulfated chondroitin sulfate, chondroitin sulfate, keratan sulfate, heparan sulfate, dextran sulfate and polysulfated pentosan.

[0016] (2) The nasal polyp reduction agent described in (1b), wherein the sulfated polysaccharide is composed of a monosaccharide selected from D-galactosamine, D-glucuronic acid, L-iduronic acid, D-glucose, D-galactose, D-xylose and L-arabinose, and the monosaccharide may be partially acetylated.

[0017] (3) The nasal polyp reducing agent according to (1b) or (2), wherein the sulfated polysaccharide is polysulfated chondroitin sulfate, polysulfated dermatan sulfate, or polysulfated pentosan.

[0018] (4) The nasal polyp reducing agent according to any one of (1) to (3), wherein the nasal polyp reducing agent is administered intranasally.

[0019] (5) A pharmaceutical composition for shrinking nasal polyps in patients with chronic sinusitis, comprising a polysaccharide or a salt thereof selected from the group consisting of polysulfated chondroitin sulfate, chondroitin sulfate, dermatan sulfate, keratan sulfate, heparan sulfate, dextran sulfate, pentosan polysulfate, chondroitin, glucomannan, inulin and xylo-oligosaccharide.

[0020] (5a) The pharmaceutical composition described in (5), wherein the polysaccharide is selected from the group consisting of polysulfated chondroitin sulfate, chondroitin sulfate, keratan sulfate, heparan sulfate, dextran sulfate, pentosan polysulfate, chondroitin, glucomannan and inulin.

[0021] (5b) A pharmaceutical composition comprising a sulfated polysaccharide or a salt thereof for use in shrinking nasal polyps in patients with chronic sinusitis.

[0022] (6) The pharmaceutical composition described in (5b), wherein the sulfated polysaccharide is composed of a monosaccharide selected from D-galactosamine, D-glucuronic acid, L-iduronic acid, D-glucose, D-galactose, D-xylose and L-arabinose, and the monosaccharide may be partially acetylated.

[0023] (7) The pharmaceutical composition described in (5b) or (6), wherein the sulfated polysaccharide is polysulfated chondroitin sulfate, polysulfated dermatan sulfate, or polysulfated pentosan.

[0024] (8) The pharmaceutical composition according to any one of (5) to (7), wherein the patient with chronic sinusitis is a patient with eosinophilic sinusitis or non-eosinophilic sinusitis.

[0025] (9) The pharmaceutical composition according to any one of (5) to (8), wherein the patient with chronic sinusitis is a patient with eosinophilic sinusitis.

[0026] (10) A preparation for intranasal administration comprising the pharmaceutical composition according to any one of (5) to (9).

[0027] (11) A method for treating nasal polyps, which is carried out by administering an effective amount of a polysaccharide or a salt thereof selected from polysulfated chondroitin sulfate, chondroitin sulfate, dermatan sulfate, keratan sulfate, heparan sulfate, dextran sulfate, pentosan polysulfate, chondroitin, glucomannan, inulin and xylo-oligosaccharide to a patient in need of treatment for nasal polyps.

[0028] (12) The method described in (11), wherein the polysaccharide or its salt is selected from the group consisting of polysulfated chondroitin sulfate, chondroitin sulfate, keratan sulfate, heparan sulfate, dextran sulfate, pentosan polysulfate, chondroitin, glucomannan and inulin.

[0029] (13) A method for reducing the size of nasal polyps, comprising administering an effective amount of sulfated polysaccharide or a salt thereof to a patient in need of treatment for nasal polyps.

[0030] (14) The method described in (13), wherein the sulfated polysaccharide or its salt is selected from polysulfated chondroitin sulfate, chondroitin sulfate, keratan sulfate, heparan sulfate, dextran sulfate and polysulfated pentosan.

[0031] (15) The method described in (13), wherein the sulfated polysaccharide is composed of monosaccharides selected from D-galactosamine, D-glucuronic acid, L-iduronic acid, D-glucose, D-galactose, D-xylose and L-arabinose, and the monosaccharides are partially acetylated.

[0032] (16) The method described in (13), wherein the sulfated polysaccharide is polysulfated chondroitin sulfate, polysulfated dermatan sulfate or polysulfated pentosan.

[0033] (17) The method described in (11), wherein the patient suffers from sinusitis.

[0034] (18) The method described in (11), wherein the patient suffers from chronic sinusitis of eosinophilic sinusitis or non-eosinophilic sinusitis.

[0035] (19) The method described in (11), wherein the patient suffers from eosinophilic sinusitis.

[0036] (20) The method described in (11) is to administer the drug into the nasal cavity.

[0037] Effects of the Invention Defined polysaccharides, particularly sulfated polysaccharides such as heparanoids or pentosan polysulfate, can be used as effective and safe nasal polyp shrinking agents at low doses. BRIEF DESCRIPTION OF THE DRAWINGS

[0038] [ Figure 1 ] shows the changes in nasal polyp weight at various doses of heparinoid (0.3, 30, and 3000 μg / mL).

[0039] [ Figure 2 ] shows the changes in nasal polyp weight at various doses of heparinoid (0.003, 0.03, 0.3, and 30 μg / mL).

[0040] [ Figure 3 ] shows the changes in nasal polyp weight at 0.003 μg / mL of pentosan polysulfate (PPS). DETAILED DESCRIPTION

[0041] Hereinafter, the present invention will be described in detail.

[0042] The polysaccharides used in the present invention include sulfated mucopolysaccharides selected from polysulfated mucopolysaccharides such as chondroitin sulfate, chondroitin sulfate, dermatan sulfate, keratan sulfate, heparan sulfate, and polysulfated chondroitin sulfate; sulfated polysaccharides further comprising dextran sulfate and pentosan polysulfate among the sulfated mucopolysaccharides; and polysaccharides selected from glucomannan, inulin, and xylo-oligosaccharides. Preferably, the polysaccharide is selected from polysulfated chondroitin sulfate, chondroitin sulfate, keratan sulfate, heparan sulfate, dextran sulfate, pentosan polysulfate, chondroitin, glucomannan, and inulin.

[0043] The sulfated polysaccharide used in the present invention is composed of monosaccharides selected from D-glucosamine, D-galactosamine, D-glucuronic acid, L-iduronic acid, D-galacturonic acid, D-glucose, D-galactose, D-xylose, and L-arabinose. These monosaccharides may be partially acetylated, and the polysaccharide containing one or more of these monosaccharides as repeating units has sulfate groups. The sulfated polysaccharide used in the present invention has an average of 0.55 to 4 sulfate groups per monosaccharide molecule, preferably an average of 0.6 to 2.9 sulfate groups, and more preferably an average of 0.7 to 2 sulfate groups.

[0044] The sulfate group content of the sulfated polysaccharide used in the present invention is preferably 10 to 70 w / w% as measured by the quantitative method specified in "Heparinoid" of the Japanese Pharmacopoeia Extramural Drug Standards 2002, and more preferably 10 to 65 w / w%.

[0045] Preferably, the main monosaccharide is selected from D-galactosamine, D-glucuronic acid, L-iduronic acid, D-glucose, D-galactose, D-xylose, and L-arabinose, and the monosaccharide is a sulfated polysaccharide that may be partially acetylated. More preferably, the sulfated polysaccharide is composed of monosaccharides selected from D-galactosamine, D-glucuronic acid, D-glucose, D-galactose, D-xylose, and L-arabinose.

[0046] Examples of partially acetylated monosaccharides include naturally occurring monosaccharides such as acetylglucose, N-acetylglucosamine, acetylgalactose, N-acetylgalactosamine, and acetylxylose.

[0047] The weight average molecular weight of the sulfated polysaccharide or its salt used in the present invention is about 1,000 to 10,000,000, preferably about 4,000 to 1,000,000.

[0048] The weight average molecular weight used in this specification refers to the value represented by the following formula when Ni polymers having a molecular weight of Mi are present: Weight average molecular weight (Mw) = Σ(Ni·Mi 2 ) / Σ(Ni·Mi).

[0049] The weight-average molecular weight refers to the value obtained by gel permeation chromatography (GPC). The weight-average molecular weight is, for example, the weight-average molecular weight of pullulan or polyethylene glycol converted by GPC determination using pullulan (pullulan) or polyethylene glycol as a standard substance. The determination of the weight-average molecular weight can be carried out, for example, by high performance liquid chromatography (Waters or Shimadzu Corporation), and Ohpak SB-804 and SB-803 (both manufactured by Showa Denko (strain)) can be used as columns. As mobile phase, aqueous solvents such as ammonium acetate aqueous solution or sodium chloride aqueous solution can be used, and the flow rate can be set to 1.0 mL / minute. Differential refractive index can be used in the detection method.

[0050] The various sulfated polysaccharides used in the present invention are obtained by the following methods.

[0051] Sulfated polysaccharides are obtained by subjecting polysaccharides composed of monosaccharides that may be partially acetylated to a sulfation reaction and introducing sulfate groups.

[0052] The sulfation reaction is carried out as follows: 10 to 30 mL of ice-cold solvent is prepared per 1 g of the raw polysaccharide. To this solvent is added a sulfating agent in an amount 2 to 6 times that of the raw polysaccharide. Then, 1 g of the raw polysaccharide is added to this solution and reacted at 0°C to 100°C for 1 to 10 hours to carry out sulfation. Examples of solvents include pyridine, N,N-dimethylformamide, and N,N-dialkylacrylamide. Examples of sulfating agents include chlorosulfonic acid and triethylamine-trisulfur trioxide complexes.

[0053] The sulfated polysaccharide composed of partially acetylated monosaccharides used in the present invention preferably has 0% to 60% (molar ratio) of the constituent sugars of the sulfated polysaccharide N-acetylated or O-acetylated.

[0054] In the present invention, the sulfated polysaccharide can be used in the form of a physiologically acceptable salt. Examples of the physiologically acceptable salt include alkali metal salts such as sodium salts and potassium salts; alkaline earth metal salts such as calcium salts; and magnesium salts, including various salts thereof.

[0055] Examples of the sulfated polysaccharide in the present invention include sulfated mucopolysaccharides, dextran sulfate, and pentosan polysulfate, etc. Preferred are polysulfated chondroitin sulfate, chondroitin sulfate, chondroitin, dermatan sulfate, keratan sulfate, heparan sulfate, dextran sulfate, and pentosan polysulfate.

[0056] In the present specification, polysulfated mucopolysaccharides such as chondroitin sulfate, chondroitin, dermatan sulfate, keratan sulfate, and heparan sulfate, as well as polysulfated chondroitin sulfate, are classified as sulfated mucopolysaccharides.

[0057] In addition, glucomannan, inulin, and xylo-oligosaccharide were classified as polysaccharides that did not meet the above criteria.

[0058] The "mucopolysaccharide" refers to a long-chain amino sugar having a basic structure of repeating units of a disaccharide composed of hexosamine and uronic acid or galactose.

[0059] "Sulfated mucopolysaccharide" refers to a mucopolysaccharide having a sulfate group. The sulfated mucopolysaccharide of the present invention also includes naturally derived mucopolysaccharides having a sulfate group in their sugar chains, and substances obtained by chemically modifying mucopolysaccharides or naturally derived sulfated mucopolysaccharides.

[0060] "Polysulfated mucopolysaccharide" refers to a sulfated mucopolysaccharide having more sulfate groups in the sugar chain, and includes polysulfated mucopolysaccharides derived from nature as well as those obtained by chemically sulfating mucopolysaccharides or natural sulfated mucopolysaccharides.

[0061] Below, the example of sulfated mucopolysaccharide is described, and its overall structure has polymorphism according to the kind of the formed proteoglycan of these sulfated mucopolysaccharides, the animal species that these sulfated mucopolysaccharides exist, tissue, developmental stage etc.That is, from natural mucopolysaccharide or sulfated mucopolysaccharide sometimes also further accept modification or its part has structure or the sugar except that basic structure in the structure of the following explanation as the basic structure of these sulfated mucopolysaccharides.These each sulfated mucopolysaccharides that use among the present invention also comprise such variant.

[0062] The term "hexosamine" broadly refers to a compound in which the hydroxyl group of a hexose is substituted with an amino group, and specific examples thereof include D-glucosamine and D-galactosamine.

[0063] In addition, "uronic acid" broadly refers to a substance obtained by oxidizing a primary alcohol of an aldose to form a carboxyl group, and specific examples thereof include naturally-occurring uronic acids such as D-glucuronic acid, L-iduronic acid, and D-galacturonic acid.

[0064] "Chondroitin sulfate" is a substance isolated from the viscous secretions or cartilage tissue of animals. Chondroitin sulfate A, C, D, and E, etc., are classified according to the bonding position between the constituent sugar and the sulfate group. However, in this specification, chondroitin sulfate A and chondroitin sulfate C are classified as sulfated mucopolysaccharides, while chondroitin sulfates D and E are sulfated mucopolysaccharides also classified as polysulfated mucopolysaccharides.

[0065] Chondroitin sulfate A (4-chondroitin sulfate) has a basic structure of a repeating disaccharide structure of N-acetyl-D-galactosamine (GalNAc) having a sulfate group at the 4-position and D-glucuronic acid (GlcA).

[0066] Chondroitin sulfate C (6-chondroitin sulfate) has a repeating structure of a disaccharide of GalNAc and GlcA having a sulfate group at the 6-position as a basic structure.

[0067] Chondroitin sulfates A and C are preferred.

[0068] Alternatively, low-molecular-weight chondroitin sulfate obtained by reducing the weight average molecular weight of chondroitin sulfate to 100,000 or less, preferably 10,000 to 50,000, can be used. Low-molecular-weight chondroitin sulfate is obtained by degrading natural chondroitin sulfate using an enzyme such as chondroitinase or chondroitin sulfate lyase.

[0069] Dermatan sulfate is composed of a repeating disaccharide of iduronic acid (IdoUA) and GalNAc, with a basic structure having a sulfate group at the 4-position of GalNAc. It is sometimes also referred to as chondroitin sulfate B.

[0070] Keratan sulfate is composed of a repeating disaccharide consisting of galactose (Gal) and N-acetyl-D-glucosamine (GlcNAc) alternately linked by β(1→4) and β(1→3) bonds, respectively. The basic structure is always sulfated at the 6th position of GlcNAc.

[0071] “Heparan sulfate” is an N-acetyl, N-sulfate, or O-sulfate substituted polysaccharide containing D-glucosamine, D-glucuronic acid, and L-iduronic acid as constituent sugars.

[0072] Chondroitin, with its basic structure consisting of a repeating disaccharide of GalNAc and GlcA, is a mucopolysaccharide with very few sulfate groups (typically less than 0.7 per disaccharide unit). Besides natural sources such as bovine cornea, chondroitin sulfate can also be obtained by chemically desulfating it.

[0073] The sulfated mucopolysaccharide used in the present invention is preferably a sulfated mucopolysaccharide having a repeating unit of a disaccharide composed of N-acetyl-D-galactosamine or N-acetyl-D-glucosamine and uronic acid or galactose, and more preferably chondroitin sulfate, dermatan sulfate, keratan sulfate, and heparan sulfate.

[0074] Furthermore, the sulfated mucopolysaccharides used in the present invention also include polysulfated mucopolysaccharides obtained by further sulfated chondroitin sulfate, dermatan sulfate, keratan sulfate, and the like.

[0075] The number of sulfate groups in the sulfated mucopolysaccharide of the present invention is not particularly limited, but each monosaccharide generally has sulfate groups at an average ratio of 0.55 to 4 molecules, preferably 0.6 to 2.9 molecules, and more preferably 0.7 to 2 molecules.

[0076] The molecular weight of the sulfated mucopolysaccharide or its salt used in the present invention varies depending on the type of polysaccharide and is not limited. However, the average molecular weight is about 10,000 to 1,000,000, preferably about 10,000 to 50,000, in terms of weight average molecular weight.

[0077] The origin of the sulfated mucopolysaccharide of the present invention is not particularly limited. More suitable sulfated mucopolysaccharides include, for example, sulfated mucopolysaccharides obtained by artificially subjecting the above-mentioned naturally derived mucopolysaccharides to a sulfation treatment.

[0078] The "polysulfated mucopolysaccharide" refers to a mucopolysaccharide in which more sulfate groups are substituted in the above-mentioned sulfated mucopolysaccharide, and specific examples thereof include polysulfated chondroitin sulfate and polysulfated dermatan sulfate. Polysulfated chondroitin sulfate is preferred.

[0079] Methods for introducing further sulfate groups into sulfated mucopolysaccharides such as chondroitin sulfate A or C to obtain polysulfated mucopolysaccharides include known methods, such as methods involving heating in the presence of a sulfating agent in a suitable solvent. The sulfating agent is not particularly limited, as long as it can achieve the desired polysulfation. Complexes of sulfuric anhydride with pyridine or triethylamine are preferred. The proportion of the sulfating agent used can be arbitrarily selected based on the desired sulfation rate (or sulfur content) of the sulfated mucopolysaccharide and the reaction conditions. It is generally used in a ratio of 2 to 10 parts by weight per 1 part by weight of the sulfated mucopolysaccharide to be polysulfated. Examples of solvents include protic solvents such as dimethylformamide. The reaction temperature and reaction time are not particularly limited, as long as the desired sulfation rate is achieved. For example, the reaction can be carried out at 40 to 90°C for 30 minutes to 20 days.

[0080] The polysulfated mucopolysaccharide produced as described above can be purified by purification procedures commonly used for various modified polysaccharides, such as neutralization, desalting by dialysis, recovery of precipitates produced by adding an organic solvent, and recovery by freeze-drying.

[0081] In the present invention, the polysulfated mucopolysaccharide can be used in the form of a physiologically acceptable salt. Examples of the physiologically acceptable salt include alkali metal salts such as sodium salts and potassium salts; alkaline earth metal salts such as calcium salts; and magnesium salts, including various salts thereof.

[0082] “Polysulfated chondroitin sulfate” refers to a polymer containing about 2 to 4 molecules, preferably about 2 to 3 molecules, of sulfate groups per disaccharide unit composed of D-acetylgalactosamine and D-glucuronic acid.

[0083] Examples of polysulfated chondroitin sulfate include chondroitin sulfate D, chondroitin sulfate E, and heparinoids listed in the Japanese Pharmacopoeia Non-drug Standards. Heparinoids listed in the Japanese Pharmacopoeia Non-drug Standards are preferred.

[0084] Polysulfated chondroitin sulfate can be easily produced by a known method, for example, by reacting chondroitin components such as chondroitin and chondroitin sulfates (A, C, D, and E) with a sulfating agent such as chlorosulfuric acid, concentrated sulfuric acid, or a sulfur trioxide-pyridine complex, in addition to naturally-occurring substances such as chondroitin sulfate D and chondroitin sulfate E.

[0085] Preferred examples of polysulfated chondroitin sulfate include heparinoids described in the Japanese Pharmacopoeia Extra-drug Ingredient Standards.

[0086] Specifically, it is polysulfated chondroitin sulfate having the following physicochemical properties: a) Sulfate content: 25.8-37.3%; b) Limiting viscosity: 0.09~0.18.

[0087] Polysulfated chondroitin sulfate can be used in the form of the free acid from the sulfate residue, but is typically used as an alkaline salt.

[0088] Examples of the alkali salt include alkali metal salts such as sodium salts and potassium salts; alkaline earth metal salts such as calcium salts; and magnesium salts.

[0089] Chondroitin sulfate D is isolated from shark cartilage and the like and has a structure similar to that of chondroitin sulfate C. Its basic structure has a sulfate group at the 2nd or 3rd position of GlcA in addition to the 6th position of GalNAc.

[0090] Chondroitin sulfate E (4,6-chondroitin sulfate) is isolated from squid cartilage and the like and has a structure similar to that of chondroitin sulfate C. Its basic structure has sulfate groups at the 4- and 6-positions of GalNAc.

[0091] "Polysulfated dermatan sulfate" refers to a substance synthesized by chemically introducing sulfate groups into dermatan sulfate, a natural sulfated mucopolysaccharide having repeating sugar units composed of N-acetylgalactosamine and L-iduronic acid, and naturally occurring polysulfated dermatan, or a substance synthesized by chemically introducing sulfate groups therein.

[0092] The number of introduced sulfate groups is not particularly limited, and examples thereof include more than one, up to four, preferably 1.3 to 4, and more preferably 2 to 4 per repeating sugar unit. The weight average molecular weight of the polysulfated dermatan sulfate of the present invention is, for example, about 1,000 to several tens of thousands.

[0093] Hereinafter, sulfated polysaccharides other than those described above that can be used in the present invention will be described.

[0094] "Dextran sulfate" is a polyanionic derivative of dextran, a polysaccharide composed of glucose units, wherein the glucose units are composed of a straight chain of glucose α(1→6) bonds and a branched chain starting from the α(1→3) bond, and the length is usually 1000 to several thousand Da to several hundred thousand Da, and the C2 to C4 positions and part of the C1 and C6 positions of the terminal groups are sulfated.

[0095] Pentosan polysulfate is a semisynthetic sulfated polysaccharide containing a mixture of polyvalent anionic polysaccharides with D-xylose and / or L-arabinose as constituent monosaccharides. Pentosan polysulfate is produced by chemically sulfating polysaccharides (e.g., xylan) obtained from woody plants, such as beech. It is generally considered to be a polysulfate of a substance with O-methyl glucuronic acid bonded to the xylan chain as a side chain.

[0096] Pentosan polysulfate can be used in the form of a physiologically acceptable salt. Examples of physiologically acceptable salts include alkali metal salts such as sodium salts and potassium salts; alkaline earth metal salts such as calcium salts; and magnesium salts. A particularly preferred salt is sodium pentosan polysulfate.

[0097] The polysulfate pentosan is not particularly limited, but preferably has a weight average molecular weight of 1,000 to 30,000, more preferably 2,000 to 10,000, and even more preferably 4,000 to 6,500.

[0098] Specific examples of polysaccharides other than sulfated polysaccharides are described below.

[0099] Glucomannan is mainly composed of glucose and mannose, which are linked by β(1→4) bonds to form a main chain, and some of them have side chains formed by β(1→3) bonds or β(1→6) bonds.

[0100] Inulin is a substance composed of 2 to 140 molecules of fructose with terminal glucose linked by β(2→1) bonds.

[0101] "Xylo-oligosaccharides" are hydrolyzed products of xylan and are oligosaccharides with a structure consisting of 2 to 7 xylose sugars linked by β(1→4) bonds. These also include xylo-oligosaccharides derived from the raw material xylan and having 4-O-methylglucuronic acid side chains, arabinofuranosyl side chains, and the like.

[0102] The polysaccharide can be used in the form of a physiologically acceptable salt. Examples of the physiologically acceptable salt include alkali metal salts such as sodium salts and potassium salts; alkaline earth metal salts such as calcium salts; and magnesium salts, including various salts thereof.

[0103] The polysaccharides can be extracted and recovered from animal or plant tissues, microorganisms such as Streptococcus microorganisms, or cultured animal or plant cells. Commercially available products can also be used.

[0104] According to the present invention, there is provided a drug effective for reducing nasal polyps, the drug comprising the above-mentioned polysaccharide, preferably the above-mentioned sulfated polysaccharide, as an active ingredient.

[0105] Furthermore, since the drug of the present invention has a nasal polyp-shrinking effect, it is also expected to improve the symptoms of diseases presenting with nasal polyps, specifically, chronic sinusitis including eosinophilic sinusitis and non-eosinophilic sinusitis, or allergic rhinitis.

[0106] Another embodiment of the present invention provides a method for treating nasal polyps, a method for shrinking nasal polyps, or a method for preventing or treating nasal polyps, wherein these methods are performed by administering the prescribed polysaccharide used in the present invention to a patient in need of treatment for nasal polyps.

[0107] Nasal polyps, also known as nasal polyposis, are fleshy growths of the nasal mucosa that develop in areas of nasal lamina propria (typically around the opening of the maxillary sinus). Treatment for nasal polyps is indicated for patients with nasal polyposis, specifically sinusitis, preferably chronic sinusitis. Chronic sinusitis includes both eosinophilic and non-eosinophilic sinusitis.

[0108] Treatment of nasal polyps includes: improving symptoms such as nasal congestion caused by nasal polyps, shrinking nasal polyps, or treating nasal polyps, that is, shrinking nasal polyps and improving symptoms such as nasal congestion.

[0109] Improving symptoms such as nasal congestion caused by nasal polyps means that, although there is no reduction in the number or size of nasal polyps, clinical symptoms such as nasal congestion are improved compared to a group not administered with the polysaccharide of the present invention.

[0110] The reduction of nasal polyps refers to at least one of the following situations: a decrease in the number of nasal polyps or a decrease in the size (area or weight of each nasal polyp) of the nasal polyps.

[0111] In the case of liquid preparations, the concentration of the polysaccharide used in the present invention is preferably 3×10 -7 The content of the soluble component is about 0.003 to 30 w / v%, more preferably about 0.003 to 10 w / v%.

[0112] The polysaccharide used in the present invention is used as an intranasal preparation and is delivered to the nasal cavity where nasal polyps are present by intranasal administration.

[0113] Intranasal preparations are pharmaceutical forms intended for intranasal administration, specifically liquid preparations, suspensions, powders, solid preparations, or semisolid preparations. Suspensions are liquid preparations containing solid particles dispersed in a liquid medium.

[0114] Preferred dosage forms of preparations for intranasal administration include nasal drops.

[0115] Nasal drops are preparations for administration to the nasal cavity or nasal mucosa and are divided into liquid and powder nasal drops. Nasal drops can be sprayed and inhaled as needed using a spray device with an appropriate spray volume and uniformity, such as a spray pump. Using a spray device with adjustable spray volume allows for adjustable nasal drop dosage.

[0116] Nasal drop liquid preparation is the liquid state to nasal cavity administration or dissolves in use or suspends in use and the solid nasal drops used, usually can be by active ingredient directly or add solvent or other suitable additives, dissolve or suspend, filter as required and manufacture.Or, can use suitable lysate or suspension liquid, dissolve in use or suspend in use and use.As required, can add cosolvent, isotonic agent, buffer agent or pH adjusting agent etc. in nasal drop liquid preparation.In addition, in the situation that suspending agent, in order to obtain the uniform state of active ingredient, can add dispersant or stabilizing agent etc. as required.

[0117] Examples of administration methods for nasal liquid preparations include spray nasal drops, nasal aerosols, or nasal atomizers. Spray nasal drops typically contain polysaccharides dissolved or suspended in a solution or mixture in an unpressurized dispenser. Spray nasal drops have the following advantages: the delivery device is small and simple, and the method of use is simple, allowing accurate measurement of a delivery dose of 25 to 200 μL. Liquids or suspensions containing polysaccharides can be used in spray nasal drops. Another intranasal method is nasal aerosols. Nasal aerosols distribute the drug due to excess pressure and release it through a valve. In spray nasal drops, the drug is forcibly distributed through a micro pump bucket, but the pressure in the vial is the same as atmospheric pressure. Nasal aerosols have the same advantages as sprays.

[0118] A nasal nebulizer is a method of administering medication using a device that uses ultrasound to form a fine mist and release the medication.

[0119] When the nasal drop liquid preparation is filled into a multiple-dose container, an appropriate preservative (antiseptic) is added as needed in an amount sufficient to prevent the growth of microorganisms. The container for the nasal drop liquid preparation is generally an airtight container.

[0120] Nasal powders are micronized nasal drops for nasal administration. They are typically manufactured by forming the active ingredient into moderately fine particles, mixing with appropriate additives if necessary, and homogenizing the mixture. Containers for nasal powders are typically sealed containers. Moisture-resistance can be applied as needed.

[0121] In addition to nasal drops, the drug of the present invention can also be prepared into solid or semisolid forms such as ointments, plasters, creams, gels, or highly viscous liquid preparations or suspensions for application to the nasal mucosa, and administered by application into the nasal cavity.

[0122] These dosage forms such as nasal drops, ointments, plasters, creams, gels, etc. are prepared by mixing the polysaccharide used in the present invention with pharmaceutically acceptable additives.

[0123] Pharmaceutically acceptable additives for the drug of the present invention include additives commonly used in the field, namely, pharmaceutical excipients and pharmaceutical carriers as shown below. These additives can be appropriately used to prepare pharmaceutical compositions suitable for respective administration forms by commonly used methods.

[0124] Pharmaceutically acceptable additives used in the drug of the present invention are not particularly limited as long as they are additives commonly used in the field. Examples thereof include bases, solubilizers, excipients, dispersants, emulsifiers, thickeners, isotonic agents, buffers, pH adjusters, stabilizers, chelating agents, preservatives, antioxidants, absorption promoters, humectants, fillers, cross-linking agents, cooling agents, and coating agents. By appropriately using these additives, pharmaceutical compositions suitable for respective administration forms can be prepared by commonly used methods.

[0125] Examples of the base for the drug of the present invention include hydrophobic bases, hydrophilic bases, and water.

[0126] The hydrophobic matrix is ​​not particularly limited, and higher hydrocarbons, oils and fats, waxes, fatty acids, higher alcohols, and fatty acid esters can be used. Examples of higher hydrocarbons include squalane, synthetic paraffin, liquid paraffin, white vaseline, and microcrystalline wax. Examples of oils and fats include sesame oil, corn oil, olive oil, and cocoa butter. Examples of waxes include beeswax, white beeswax, lanolin, reduced lanolin, and ozokerite. Examples of fatty acids include stearic acid and oleic acid. Examples of higher alcohols include lanolin alcohol, myristyl alcohol, cetyl alcohol, stearyl alcohol, cetearyl alcohol, and cholesterol. Examples of fatty acid esters include isopropyl myristate, stearyl myristate, and medium-chain fatty acid triglycerides.

[0127] Examples of the hydrophilic base include ethanol, propanol, isopropanol, butanol, isobutanol, propylene glycol, polyethylene glycol, and macrogol.

[0128] The solubilizing agent is not particularly limited, and examples thereof include propylene glycol, D-mannitol, benzyl benzoate, ethanol, isopropyl alcohol, triethanolamine, sodium carbonate, and sodium citrate.

[0129] When the drug of the present invention is a powder for nasal drops, an excipient is used as an additive as necessary.

[0130] The excipient is not particularly limited, and examples thereof include sugar alcohols such as erythritol, maltitol, mannitol, sorbitol, xylitol, and lactitol; sugars such as refined sugar (white sugar), lactose, reduced maltose syrup, powdered reduced maltose syrup, glucose, and maltose; corn starch, crystalline cellulose, calcium monohydrogen phosphate, calcium hydrogen phosphate, anhydrous calcium hydrogen phosphate, light silicic acid anhydride, hydrated silicon dioxide, and silicon dioxide.

[0131] When the drug of the present invention is in the form of a suspension, a dispersant is used as an additive as necessary.

[0132] The dispersant is not particularly limited, and examples thereof include: celluloses such as methylcellulose, sodium carboxymethylcellulose, and hydroxypropyl methylcellulose; synthetic polymers such as polyvinyl alcohol, polyvinyl pyrrolidone, and carboxyvinyl polymers; nonionic surfactants such as polyoxyethylene alkyl ethers, polyoxyethylene polypropylene alkyl ethers, sorbitan fatty acid esters, polyoxyethylene sorbitan fatty acid esters, glycerol fatty acid esters, polyglycerol fatty acid esters, polyoxyethylene glycerol fatty acid esters, polyethylene glycol fatty acid esters, sucrose fatty acid esters, polyoxyethylene castor oil, polyoxyethylene hydrogenated castor oil, and polyoxyethylene polyoxypropylene polymers; amphoteric surfactants such as alkyl betaines, alkyl amide betaines, alkyl sulfobetaines, and imidazolines; and anionic surfactants such as saturated higher fatty acid salts, alkyl sulfonates, alkyl ether sulfonates, and polyoxyethylene alkyl ether phosphates.

[0133] Examples of the emulsifier include cationic surfactants, anionic surfactants, amphoteric surfactants, and nonionic surfactants.

[0134] The cationic surfactant is not particularly limited, and examples thereof include cetyltrimethylammonium chloride, dodecyldimethylbenzylammonium chloride, tetrabutylammonium chloride, and dioctadecyldimethylammonium chloride.

[0135] The anionic surfactant is not particularly limited, and examples thereof include sodium alkylbenzenesulfonate, sodium lauryl sulfate, sodium coconut ethoxysulfate, sodium α-olefinsulfonate, and emulsified cetearyl alcohol.

[0136] The nonionic surfactant is not particularly limited, and examples thereof include polyoxyethylene alkyl ethers, polyoxyethylene alkylphenol ethers, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene hydrogenated castor oil, polyoxyethylene stearate, glycerol fatty acid esters, and diglycerol fatty acid esters.

[0137] The amphoteric surfactant is not particularly limited, and examples thereof include N-alkyl-N,N-dimethylammonium betaine and imidazoline-type amphoteric surfactants.

[0138] The above surfactants can be used alone or in combination.

[0139] The thickener is not particularly limited, and examples thereof include sodium alginate, gelatin, methylcellulose, carboxyvinyl polymer, carboxymethylcellulose, and sodium polyacrylate.

[0140] The isotonic agent is not particularly limited, and examples thereof include sugars such as sorbitol, glucose, and mannitol; polyols such as glycerol, polyethylene glycol, and propylene glycol; and inorganic salts such as sodium chloride and potassium chloride.

[0141] The buffer is not particularly limited, and examples thereof include boric acid, borax, sodium monohydrogen phosphate, sodium dihydrogen phosphate, citric acid, sodium citrate, sodium dihydrogen citrate, and disodium citrate.

[0142] The pH adjuster is not particularly limited, and examples thereof include diisopropanolamine, triisopropanolamine, triethanolamine, potassium hydroxide, sodium hydroxide, sodium citrate, phosphoric acid, tartaric acid, dl-malic acid, and glacial acetic acid.

[0143] The stabilizer is not particularly limited, and examples thereof include sodium edetate, sodium oleate, casein, and casein sodium salt.

[0144] The chelating agent is not particularly limited, and examples thereof include edetic acid, oxalic acid, citric acid, pyrophosphoric acid, hexametaphosphoric acid, gluconic acid, and salts thereof.

[0145] The preservative is not particularly limited, and examples thereof include quaternary ammonium salts such as benzalkonium chloride, benzoxonium chloride, benzododecinium bromide, benzethonium chloride, cetylpyridinium chloride, and cetrimide; C1-C7 alkyl esters of 4-hydroxybenzoic acid and their salts such as benzoic acid and its salts, methyl 4-hydroxybenzoate, and propyl 4-hydroxybenzoate; chlorhexidine and its intranasally acceptable salts such as chlorhexidine digluconate, chlorhexidine acetate, and chlorhexidine chloride; 2-phenylethanol, 2-phenoxyethanol, chlorobutanol, and sorbic acid.

[0146] As the preservative, an intranasally acceptable preservative is preferred.

[0147] The antioxidant is not particularly limited, and examples thereof include polyphenols, ascorbic acid, t-butylhydroquinone, butylated hydroxyanisole, butylated hydroxytoluene, L-cysteine ​​hydrochloride, sodium bisulfite, and α-tocopherol and its derivatives.

[0148] The absorption enhancer is not particularly limited, and examples thereof include diisopropyl adipate, lecithin, squalane, squalene, l-menthol, polyethylene glycol, isopropyl myristate, dimethyl sulfoxide, peppermint oil, eucalyptus oil, d-limonene, and dl-limonene.

[0149] The moisturizing agent is not particularly limited, and examples thereof include glycerin, propylene glycol, and 1,3-butylene glycol.

[0150] The filler is not particularly limited, and examples thereof include kaolin, titanium dioxide, and zinc oxide.

[0151] The cross-linking agent is not particularly limited, and examples thereof include acetaldehyde, dimethyl ketone, and aluminum sulfate.

[0152] The cooling agent is not particularly limited, and examples thereof include l-menthol, dl-camphor, d-borneol, anise oil, peppermint oil, and mint water.

[0153] The nasal drop liquid formulation containing the drug of the present invention may include a nasally acceptable coating agent. If a coating agent is added, the moisturizing effect and pain-relieving effect of the composition of the present invention can be enhanced by inhibiting water loss to maintain a good hydration level of the nasal mucosa for a longer period of time.

[0154] The coating agent is not particularly limited, and examples thereof include cellulose materials that are soluble or swellable in water, such as hydroxypropyl methylcellulose, hydroxypropyl cellulose, methylcellulose, hydroxyethyl methylcellulose, and sodium carboxymethylcellulose; polyvinyl pyrrolidone (povidone) and cross-linked polyvinyl pyrrolidone (crospovidone).

[0155] The drug of the present invention varies depending on the patient's age, weight, sex, degree (amount, range) of nasal polyps, etc., and is not particularly limited. The dosage varies depending on the degree of nasal polyps.

[0156] 5×10 -11 Apply 1g to the nasal cavity once or several times.

[0157] It should be noted that, since chronic sinusitis, especially eosinophilic sinusitis, is closely related to asthma, the drug of the present invention can be administered in combination with an asthma therapeutic drug to patients with chronic sinusitis complicated by asthma.

[0158] Asthma therapeutic drugs include, for example, the following drugs.

[0159] Inhaled steroids or nasal spray steroids: beclomethasone propionate, fluticasone propionate, budesonide, ciclesonide, mometasone furan carboxylate, etc. Combination medications of inhaled steroids and long-acting beta-2 agonists: Combination medication with salmeterol xinafoate and combination medication with formoterol fumarate hydrate; Theophylline sustained-release preparations: Theodur (theophylline sustained-release tablets), Theolong, Slo-bid (anhydrous theophylline long-acting preparation), Uniphyl, Unicon, Neophyllin, Theodrip, etc. Short-acting theophylline drugs: Neophyllin, Theocolin, Monophylline, Asthmolysin-D / M, Asthphyllin, Albina suppositories, etc. Long-acting beta-2 agonists: inhalers (LABA) / Serevent, patches / Hokunalin strips, oral medications / Meptin, Spiropent, Hokunalin, Berachin, Atock, Broncholin, etc. Short-acting beta-2 agonists (SABA): inhalers / Airomir, Sultanol, Meptin Air, Berotec aerosol, etc., oral medications / Venetlin, Alotec, Inolin, LEANOL, ephedrine, Isopal P, etc.; Leukotriene antagonists (receptor antagonists): Onon, Accolate, Singulair, Kipres, etc.; Th2 cytokine inhibitors: IPD, etc.; Histamine H1 receptor antagonists: Zesulan, Nipolazin, Zaditen, Celtect, Alesion, etc.; Mediator release inhibitors: Intal, Rizaben, Solfa, Romet, Ketas, Alegysal, Pemilaston, Tazanol, Tazalest, etc.; Thromboxane A2 inhibitors: Vega, Domenan, etc.; Thromboxane A2 antagonists: Bronica, Baynas, etc.; Oral steroids: prednisone, prednisolone, Medrol (methylprednisolone), Rinderon, Ledercort, Decadron, Corson, dexamethasone, paramethasone, etc. Immunosuppressive drugs: cyclosporine, etc. Interleukin-4R (IL-4R) inhibitors: dupilumab, etc. Iodine preparations: Jolethin (Voliti), etc.

[0160] The drug of the present invention can also be administered in combination with a vasoconstrictor. Examples of vasoconstrictors include naphazoline hydrochloride, tetrahydrozoline hydrochloride, phenylephrine hydrochloride, epinephrine hydrochloride, dl-methylephedrine hydrochloride, tetrahydrozoline nitrate, naphazoline nitrate, and epinephrine. Example

[0161] Hereinafter, the present invention will be described in further detail based on the following examples. It should be noted that the present invention is not limited to the following examples.

[0162] [Example 1] The nasal polyp-shrinking effect of heparinoids on nasal polyps in patients with eosinophilic sinusitis Heparinoids (organic sulfate groups of 25.8-37.3% w / w, D-glucuronic acid of 19.0-24.0% w / w, Maruho Co., Ltd.) dried under reduced pressure were dissolved in physiological saline to prepare heparinoid solutions (0.3, 30, and 3000 μg / mL). Nasal polyp samples taken from patients with eosinophilic sinusitis were finely cut into approximately 5 mm squares, wiped off the moisture, and the weight was measured. Each sample was transferred to a 12-well plate, 1 mL of physiological saline or heparinoid solutions of various concentrations was added, and cultured at 37°C for about 24 hours. The samples were removed from the plate, the moisture was wiped off, and the weight was measured. The difference in sample weight before and after culture was used as an indicator of the nasal polyp-shrinking effect for evaluation. In addition, Figure 1 The number of cases in the normal saline group and the heparinoid solution groups of various concentrations was 6.

[0163] The changes in sample weight before and after culture are shown in Figure 1 . Figure 1 The * and ** in the figure indicate significant differences in nasal polyp weight before and after culture based on a paired t-test (*p < 0.05, **p < 0.01). While no significant changes in nasal polyp weight were observed in culture with saline, nasal polyp weight was significantly reduced in culture with heparinoid solutions (0.3, 30, and 3000 μg / mL), suggesting that heparinoids have a polyp-shrinking effect.

[0164] [Example 2] Nasal polyp-reducing effect of heparinoids on nasal polyps in patients with eosinophilic sinusitis The nasal polyp-reducing effect of 0.003, 0.03, 0.3, and 30 μg / mL heparinoid solutions was evaluated in the same manner as in Example 1. Figure 2 The number of cases in the normal saline group and the heparinoid solution groups of various concentrations was 6.

[0165] The changes in sample weight before and after culture are shown in Figure 2 . Figure 2 ** indicates a significant difference in nasal polyp weight before and after culture as determined by a paired t-test (**p < 0.01). While no significant change in nasal polyp weight was observed with saline incubation, nasal polyp weight was significantly reduced with heparinoid solutions (0.003, 0.03, 0.3, and 30 μg / mL), suggesting that heparinoids have a polyp-shrinking effect.

[0166] [Example 3] Effect of Pentosan Polysulfate (PPS) on Nasal Polyps in Patients with Eosinophilic Sinusitis A PPS solution (0.003 μg / mL) was prepared in the same manner as in Example 1, and the nasal polyp-reducing effect was evaluated. Pentosan polysulfate sodium (weight-average molecular weight of 4000-6500, sulfur content of 13.0-20.0% w / w, glucuronic acid content of 2.5-4.0% w / w) manufactured by Molclone Labs was used as PPS. Figure 3 The number of cases in the normal saline group and PPS solution group was 6.

[0167] The changes in sample weight before and after culture are shown in Figure 3 While almost no reduction in nasal polyp weight was observed in culture with saline, a significant reduction in nasal polyp weight was observed in culture with PPS solution (0.003 μg / mL), suggesting that PPS has a shrinking effect on nasal polyps in patients with eosinophilic sinusitis.

[0168] [Example 4] Nasal Polyp Reduction Effect of Various Polysaccharides on Nasal Polyps in Patients with Eosinophilic Sinusitis Using the same method as in Example 1, the following 11 polysaccharide solutions (300 μg / mL for each of the other polysaccharide solutions except glucomannan and 30 μg / mL for glucomannan) were prepared and their nasal polyp reduction effects were evaluated. The saline group and each polysaccharide solution group in Tables 1 to 4 each included a single patient.

[0169] Chondroitin (sodium chondroitin, weight-average molecular weight 42,351, sulfate content 2.6%, manufactured by Maruho Co., Ltd.); Low-molecular-weight chondroitin sulfate (low-molecular-weight chondroitin sulfate sodium, weight-average molecular weight 11,500, sulfate content 8.9%, manufactured by Maruho Co., Ltd.); Chondroitin sulfate A (sodium chondroitin sulfate A, manufactured by PG Research Co., Ltd.); Dermatan sulfate (sodium dermatan sulfate, manufactured by Tokyo Chemical Industry Co., Ltd.); Chondroitin sulfate C (sodium chondroitin sulfate C, manufactured by PG Research Co., Ltd.); Glucomannan (Propol A, manufactured by Shimizu Chemical Co., Ltd.); Dextran sulfate (dextran sulfate sodium 500,000, manufactured by Fujifilm Wako Pure Chemical Industries, Ltd.); Keratan sulfate (sodium keratan sulfate, manufactured by PG Research Co., Ltd.); Inulin (manufactured by Tokyo Chemical Industry Co., Ltd.); Heparan sulfate (manufactured by Toronto Research Chemicals, Inc.); Xylo-oligosaccharide (xylohexaose, manufactured by Megazyme).

[0170] Chondroitin was synthesized by desulfating sodium chondroitin sulfate (manufactured by Bioiberica) using the same method as in Japanese Patent Application Laid-Open No. 07-062001. Low-molecular-weight chondroitin sulfate was synthesized by hydrolyzing sodium chondroitin sulfate (manufactured by Bioiberica) under acidic conditions. Other polysaccharides used were commercially available products as described.

[0171] Changes in sample weight before and after culture are shown in Tables 1 to 4. While nasal polyp weight was barely reduced in culture with saline, nasal polyp weight was significantly reduced in culture with 11 polysaccharide solutions (300 μg / mL for all polysaccharides except glucomannan and 30 μg / mL for glucomannan), suggesting that the 11 polysaccharides have a role in shrinking nasal polyps in patients with eosinophilic sinusitis.

[0172] [Table 1] [Table 2] [Table 3] [Table 4] [Example 5] Nasal Polyp Reduction Effects of Heparinoids and PPS on Nasal Polyps in Patients with Non-eosinophilic Sinusitis Heparinoid solutions and PPS solutions (0.03, 0.3, 30, and 300 μg / mL, respectively) were prepared using the same method as in Example 1, and their nasal polyp reduction effects were evaluated on nasal polyp specimens collected from patients with non-eosinophilic sinusitis. The heparinoids and PPS used were the same as those used in Examples 1 and 3. The number of patients in the saline group, heparinoid solution group, and PPS solution group in Table 5 is one.

[0173] Changes in sample weight before and after culture are shown in Table 5. While no decrease in nasal polyp weight was observed with incubation with saline, significant decreases in nasal polyp weight were observed with incubation with heparinoid solution and PPS solution (0.03, 0.3, 30, and 300 μg / mL, respectively), suggesting that heparinoids and PPS also have a shrinking effect on nasal polyps in patients with non-eosinophilic sinusitis.

[0174] [Table 5] Industrial Applicability A certain polysaccharide including heparanoid as a sulfated polysaccharide shows a significant effect on nasal polyps at a low dose, and thus the prescribed polysaccharide including sulfated polysaccharide can be used as a nasal polyp reducing agent for the treatment or prevention of patients with chronic sinusitis with nasal polyps.

Claims

1. A nasal polyp reducing agent, comprising a polysaccharide or a salt thereof selected from polysulfated chondroitin sulfate, chondroitin sulfate, dermatan sulfate, keratan sulfate, heparan sulfate, dextran sulfate, pentosan polysulfate, chondroitin, glucomannan, inulin and xylo-oligosaccharide as an effective ingredient.

2. The nasal polyp reducing agent according to claim 1, wherein The polysaccharide is selected from the group consisting of polysulfated chondroitin sulfate, chondroitin sulfate, keratan sulfate, heparan sulfate, dextran sulfate, pentosan polysulfate, chondroitin, glucomannan and inulin.

3. The nasal polyp reducing agent according to claim 1 or 2, which is administered intranasally.

4. A pharmaceutical composition for shrinking nasal polyps in patients with chronic sinusitis, comprising a polysaccharide or a salt thereof selected from the group consisting of polysulfated chondroitin sulfate, chondroitin sulfate, dermatan sulfate, keratan sulfate, heparan sulfate, dextran sulfate, polysulfated pentosan, chondroitin, glucomannan, inulin and xylo-oligosaccharide.

5. The pharmaceutical composition according to claim 4, wherein The polysaccharide is selected from the group consisting of polysulfated chondroitin sulfate, chondroitin sulfate, keratan sulfate, heparan sulfate, dextran sulfate, pentosan polysulfate, chondroitin, glucomannan and inulin.

6. The pharmaceutical composition according to claim 4 or 5, wherein The above-mentioned chronic sinusitis patients are patients with eosinophilic sinusitis or non-eosinophilic sinusitis.

7. The pharmaceutical composition according to any one of claims 4 to 6, wherein The above-mentioned chronic sinusitis patients are patients with eosinophilic sinusitis.

8. A preparation for intranasal administration, comprising the pharmaceutical composition according to any one of claims 4 to 7.